SS
ALLO icon

SBI Securities’s Allogene Therapeutics ALLO Stock Holding History

SBI Securities’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11K Buy
536
+105
+24% +$231 ﹤0.01% 2768
2026
Q1 		$1.05K Hold
431
– – ﹤0.01% 2639
2025
Q4 		$590 Hold
431
– – ﹤0.01% 2810
2025
Q3 		$534 Sell
431
-100
-19% -$119 ﹤0.01% 2939
2025
Q2 		$600 Buy
531
+106
+25% +$141 ﹤0.01% 2895
2025
Q1 		$621 Hold
425
– – ﹤0.01% 2777
2024
Q4 		$905 Buy
+425
New +$1.05K ﹤0.01% 2657

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SBI Securities's ALLO Position: Q2 2026 in Review

SBI Securities increased its Allogene Therapeutics (ALLO) stake by 24% in Q2 2026, buying an estimated $231 and bringing the position to 536 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

SBI Securities first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • SBI Securities held 536 shares of Allogene Therapeutics worth $1.11K as of Q2 2026.
  • SBI Securities bought 105 Allogene Therapeutics shares in Q2 2026, an estimated $231.
  • Allogene Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2768 holding.
  • SBI Securities first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.